Lisa Hanner-Robinson
General Practice · Bloomington, INNPI 1255336160
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.2% of the total across 533 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 45 manufacturers reported payments, led by AbbVie at 27.0% of the total. Among general practice clinicians in IN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 533 payments — averaging $16.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Novo Nordisk$848
- Lilly USA, LLC$819
- Pfizer$424
- Corcept Therapeutics$403
- Amgen$389
- plus $3K from 39 others
What the payments were for
- Food & beverage$8,43198%
- Education$1562%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$8,587 in reported general payments places this provider in the 95th percentile of 1,558 general practice providers in Indiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 14 | $13,450 |
| MounjaroTirzepatide | 11 | $11,910 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 38 | $1,063 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 21 | $958 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 21 | $943 |
| Ezetimibe | 17 | $554 |
| Gabapentin | 24 | $381 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 15 | $317 |
| Zolpidem Tartrate | 30 | $276 |
| Levothyroxine Sodium | 52 | $229 |
| Losartan Potassium | 13 | $227 |
| Lisinopril | 38 | $226 |
| Meloxicam | 36 | $213 |
| Pravastatin Sodium | 14 | $179 |
| Potassium Chloride | 13 | $158 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $819 | $11,91011 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $218 | $22952 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,558 general practice providers in Indiana.
Other general practice in Bloomington
- Kelly JastremskiBloomington$7K
- Martin BarcoBloomington$6K
- Tina GermanWarsaw$260K
- Kenneth TroutmanHuntingburg$124K
- Roger JonesClinton$78K
- Daniel KlauerGranger$45K
- William FloraElkhart$39K
- Ryan HolmesFort Wayne$33K
- Samuel CoreyFort Wayne$27K
- Kara WulffMuncie$23K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.